147 related articles for article (PubMed ID: 38634916)
1. COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
Thau S; Poulsen CB; Brieghel C; Larsen MK; Wiese L; Nielsen XC; Pedersen LM
Ann Hematol; 2024 Apr; ():. PubMed ID: 38634916
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
3. Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience.
Laurenti L; Scarfò L; Frustaci AM; Sanna A; Iannella E; Caira M; Finsinger P; Schifano S; Neri B; Molica S; Mauro FR
Hematol Oncol; 2023 Oct; 41(4):621-630. PubMed ID: 36680368
[TBL] [Abstract][Full Text] [Related]
4. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
Frustaci AM; Del Poeta G; Visentin A; Sportoletti P; Fresa A; Vitale C; Murru R; Chiarenza A; Sanna A; Mauro FR; Reda G; Gentile M; Varettoni M; Baratè C; Borella C; Greco A; Deodato M; Zamprogna G; Laureana R; Cipiciani A; Galitzia A; Curto Pelle A; Morelli F; Malvisi L; Coscia M; Laurenti L; Trentin L; Montillo M; Cairoli R; Tedeschi A
Ther Adv Hematol; 2022; 13():20406207221127550. PubMed ID: 36246422
[TBL] [Abstract][Full Text] [Related]
5. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
[TBL] [Abstract][Full Text] [Related]
6. Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.
Mauro FR; Giannarelli D; Galluzzo CM; Visentin A; Frustaci AM; Sportoletti P; Vitale C; Reda G; Gentile M; Levato L; Murru R; Armiento D; Molinari MC; Proietti G; Pepe S; De Falco F; Mattiello V; Barabino L; Amici R; Coscia M; Tedeschi A; Girmenia C; Trentin L; Baroncelli S
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296954
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
8. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Niemann CU; da Cunha-Bang C; Helleberg M; Ostrowski SR; Brieghel C
Blood; 2022 Aug; 140(5):445-450. PubMed ID: 35588468
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Popławska L; Morawska M; Tryc-Szponder J; Bołkun Ł; Rybka J; Pruszczyk K; Juda A; Majeranowski A; Iskierka-Jażdżewska E; Steckiewicz P; Wdowiak K; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
Ann Hematol; 2023 Aug; 102(8):2119-2126. PubMed ID: 37392368
[TBL] [Abstract][Full Text] [Related]
11. The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.
Yang S; Wei R; Shi H; Wang Y; Lai Y; Zhao X; Lu J; Schmitz N
Front Oncol; 2024; 14():1396913. PubMed ID: 38835372
[TBL] [Abstract][Full Text] [Related]
12. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
13. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Scarfò L; Chatzikonstantinou T; Rigolin GM; Quaresmini G; Motta M; Vitale C; Garcia-Marco JA; Hernández-Rivas JÁ; Mirás F; Baile M; Marquet J; Niemann CU; Reda G; Munir T; Gimeno E; Marchetti M; Quaglia FM; Varettoni M; Delgado J; Iyengar S; Janssens A; Marasca R; Ferrari A; Cuéllar-García C; Itchaki G; Špaček M; De Paoli L; Laurenti L; Levin MD; Lista E; Mauro FR; Šimkovič M; Van Der Spek E; Vandenberghe E; Trentin L; Wasik-Szczepanek E; Ruchlemer R; Bron D; De Paolis MR; Del Poeta G; Farina L; Foglietta M; Gentile M; Herishanu Y; Herold T; Jaksic O; Kater AP; Kersting S; Malerba L; Orsucci L; Popov VM; Sportoletti P; Yassin M; Pocali B; Barna G; Chiarenza A; Dos Santos G; Nikitin E; Andres M; Dimou M; Doubek M; Enrico A; Hakobyan Y; Kalashnikova O; Ortiz Pareja M; Papaioannou M; Rossi D; Shah N; Shrestha A; Stanca O; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Coscia M; Stamatopoulos K; Rossi G; Rambaldi A; Montserrat E; Foà R; Cuneo A; Ghia P
Leukemia; 2020 Sep; 34(9):2354-2363. PubMed ID: 32647324
[TBL] [Abstract][Full Text] [Related]
15. Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia.
Puła B; Pruszczyk K; Pietrusza E; Morawska M; Piszczek W; Kalicińska E; Szeremet A; Tryc-Szponder J; Wąsik-Szczepanek E; Drozd-Sokołowska J; Krzemień H; Rejus A; Gajewska M; Wiśniewski K; Wysocki M; Majeranowski A; Paszkiewicz-Kozik E; Steckiewicz P; Szukalski Ł; Bołkun Ł; Długosz-Danecka M; Giannopoulos K; Jamroziak K; Lech-Marańda E; Hus I
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158826
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
Diamantopoulos PT; Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Giannakopoulou N; Vardaka M; Mpouhla A; Mastrogianni E; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ther Adv Hematol; 2022; 13():20406207221090150. PubMed ID: 35646300
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
19. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
20. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
